Lipoprotein(a) in High-Risk Primary Prevention: Making the Best of What We Have

This publication has 13 references indexed in Scilit:

• 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
  Circulation, 2026
• Evolocumab in Patients without a Previous Myocardial Infarction or Stroke
  New England Journal of Medicine, 2026
• Demographics of lipoprotein(a) and stroke: The UK biobank
  American Journal of Preventive Cardiology, 2025
• High lipoprotein(a): Actionable strategies for risk assessment and mitigation
  American Journal of Preventive Cardiology, 2024
• Lipoprotein(a) Is Markedly More Atherogenic Than LDL
  JACC, 2024
• Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
  New England Journal of Medicine, 2022
• Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
  JACC, 2020
• Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2020
• Association ofLPAVariants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies
  JAMA Cardiology, 2018
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
  The Lancet, 2010